Efficacy of anti-IL-5 monoclonal antibody for chronic rhinosinusitis with nasal polyps and comorbid asthma

Efficacy of anti-IL-5 monoclonal antibody for chronic rhinosinusitis with nasal polyps and comorbid asthma - efficacy of anti-IL-5 monoclonal antibody for chronic rhinosinusitis with nasal polyps

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057664

Enrollment

Registered

2025-04-20

Start date

2025-04-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic rhinosinusitis with nasal polyps

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Chronic rhinosinusitis with nasal polyps and comorbid asthma refractory to conventional therapy 2.Male and female participants between the ages of 18 and 79 years

Exclusion criteria

Exclusion criteria: 1.Patients who are pregnant or may be pregnant 2.Patients who are unable to provide informed consent

Design outcomes

Primary

Measure	Time frame
Changes in olfactory testing from baseline to 48 weeks of mepolizumab therapy	—

Secondary

Measure	Time frame
Changes in nasal symptoms, questionnaire scores, nasal polyp scores, sinonasal computed tomography scoring, pulmonary function, blood test, airway hyperresponsiveness and mucus plugging from baseline to 48 weeks of mepolizumab therapy	—

Countries

Japan

Contacts

Public ContactTomoko Tajiri

Nagoya City University Graduate School of Medical Sciences Department of Respiratory Medicine, Allergy and Clinical Immunology

tomokot@med.nagoya-cu.ac.jp052-853-8216

Outcome results